Evidence map›Paper›PMID 27196440›Full record

ArticlePloS one2016

Common miR-590 Variant rs6971711 Present Only in African Americans Reduces miR-590 Biogenesis.

Xiaoping Lin, Steven Steinberg, Suresh K Kandasamy, Junaid Afzal, Blaid Mbiyangandu, Susan E Liao, Yufan Guan, Celia P Corona-Villalobos, Scot J Matkovich, Neal Epstein and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. RNA biology · 2019
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Xiaoping LinHypertrophic Cardiomyopathy Center of Excellence, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Steven SteinbergInstitute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Suresh K KandasamyDepartment of Biological Chemistry, Johns Hopkins School of Medicine, Baltimore, MD, United States of America.
Junaid AfzalHypertrophic Cardiomyopathy Center of Excellence, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Blaid MbiyanganduHypertrophic Cardiomyopathy Center of Excellence, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Susan E LiaoDepartment of Biological Chemistry, Johns Hopkins School of Medicine, Baltimore, MD, United States of America.
Yufan GuanHypertrophic Cardiomyopathy Center of Excellence, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Celia P Corona-VillalobosHypertrophic Cardiomyopathy Center of Excellence, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Scot J MatkovichCenter for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States of America.
Neal EpsteinLaboratory of Molecular Cardiology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.
Dotti TripodiLaboratory of Molecular Cardiology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.
Zhaoxia HuoClinical Research Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Garry CuttingInstitute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Theodore P AbrahamHypertrophic Cardiomyopathy Center of Excellence, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Ryuya FukunagaDepartment of Biological Chemistry, Johns Hopkins School of Medicine, Baltimore, MD, United States of America.ORCID 0000-0002-5814-8206
M Roselle AbrahamHypertrophic Cardiomyopathy Center of Excellence, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Johns Hopkins University · USNational Institutes of Health · USWashington University in St. Louis · USZhejiang University · CN

Funding

Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
Development of a Hypertrophic Cardiomyopathy ConsortiumR01HL098046 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ABRAHAM, THEODORE P · 2010 to 2012
$953k
NCRR NIH HHS UL1 RR025005NHLBI NIH HHS R01 HL098046NIGMS NIH HHS T32 GM007445
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are recognized as important regulators of cardiac development, hypertrophy and fibrosis. Recent studies have demonstrated that genetic variations which cause alterations in miRNA:target interactions can lead to disease. We hypothesized that genetic variations in miRNAs that regulate cardiac hypertrophy/fibrosis might be involved in generation of the cardiac phenotype in patients diagnosed with hypertrophic cardiomyopathy (HCM). To investigate this question, we Sanger sequenced 18 miRNA genes previously implicated in myocyte hypertrophy/fibrosis and apoptosis, using genomic DNA isolated from the leukocytes of 199 HCM patients. We identified a single nucleotide polymorphism (rs6971711, C57T SNP) at the 17th position of mature miR-590-3p (= 57th position of pre-miR-590) that is common in individuals of African ancestry. SNP frequency was higher in African American HCM patients (n = 55) than ethnically-matched controls (n = 100), but the difference was not statistically significant (8.2% vs. 6.5%; p = 0.5). Using a cell culture system, we discovered that presence of this SNP resulted in markedly lower levels of mature miR-590-5p (39 ± 16%, p<0.003) and miR-590-3p (20 ± 2%, p<0.003), when compared with wild-type (WT) miR-590, without affecting levels of pri-miR-590 and pre-miR-590. Consistent with this finding, the SNP resulted in reduced target suppression when compared to WT miR-590 (71% suppression by WT vs 60% suppression by SNP, p<0.03). Since miR-590 can regulate TGF-β, Activin A and Akt signaling, SNP-induced reduction in miR-590 biogenesis could influence cardiac phenotype by de-repression of these signaling pathways. Since the SNP is only present in African Americans, population studies in this patient population would be valuable to investigate effects of this SNP on myocyte function and cardiac physiology.

Indexed as

Polymorphism, Single NucleotideBlack or African AmericanCardiomyopathy, HypertrophicCase-Control StudiesHEK293 CellsHumansMicroRNAsMyocytes, CardiacMicroRNAsMIRN590 microRNA, human

Identifiers

PMID27196440
PMCPMC4873136
OpenAlexW2398300723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.